Have a feature idea you'd love to see implemented? Let us know!

JAZZ Jazz Pharmaceuticals plc

Price (delayed)

$122.59

Market cap

$7.41B

P/E Ratio

16.46

Dividend/share

N/A

EPS

$7.45

Enterprise value

$11.38B

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights
Jazz Pharmaceuticals's quick ratio has soared by 130% YoY and by 88% from the previous quarter
Jazz Pharmaceuticals's equity has increased by 20% YoY and by 11% from the previous quarter
The company's debt rose by 7% QoQ and by 7% YoY

Key stats

What are the main financial stats of JAZZ
Market
Shares outstanding
60.45M
Market cap
$7.41B
Enterprise value
$11.38B
Valuations
Price to book (P/B)
1.81
Price to sales (P/S)
1.89
EV/EBIT
17.4
EV/EBITDA
8.72
EV/Sales
2.85
Earnings
Revenue
$3.99B
EBIT
$653.72M
EBITDA
$1.3B
Free cash flow
$1.13B
Per share
EPS
$7.45
Free cash flow per share
$18.4
Book value per share
$67.54
Revenue per share
$65.01
TBVPS
$86.41
Balance sheet
Total assets
$12.26B
Total liabilities
$8.08B
Debt
$6.18B
Equity
$4.17B
Working capital
$3.36B
Liquidity
Debt to equity
1.48
Current ratio
4.26
Quick ratio
3.24
Net debt/EBITDA
3.04
Margins
EBITDA margin
32.7%
Gross margin
89.4%
Net margin
11.6%
Operating margin
16.2%
Efficiency
Return on assets
4%
Return on equity
12.1%
Return on invested capital
8.8%
Return on capital employed
5.8%
Return on sales
16.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-0.45%
1 week
0.82%
1 month
9.9%
1 year
0.79%
YTD
-0.33%
QTD
10.04%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$3.99B
Gross profit
$3.57B
Operating income
$648.36M
Net income
$463.16M
Gross margin
89.4%
Net margin
11.6%
Jazz Pharmaceuticals's net income has increased by 17% QoQ
The operating income rose by 16% since the previous quarter
The company's net margin rose by 15% QoQ
JAZZ's operating margin is up by 13% since the previous quarter

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
P/E
16.46
P/B
1.81
P/S
1.89
EV/EBIT
17.4
EV/EBITDA
8.72
EV/Sales
2.85
The company's EPS rose by 19% QoQ
The P/E is 11% lower than the last 4 quarters average of 18.4
The price to book (P/B) is 25% lower than the 5-year quarterly average of 2.4 and 4.7% lower than the last 4 quarters average of 1.9
Jazz Pharmaceuticals's equity has increased by 20% YoY and by 11% from the previous quarter
The price to sales (P/S) is 30% less than the 5-year quarterly average of 2.7
The revenue has grown by 5% YoY and by 2.1% from the previous quarter

Efficiency

How efficient is Jazz Pharmaceuticals business performance
The company's return on assets rose by 14% QoQ
The company's return on sales rose by 13% QoQ
The return on equity has increased by 12% since the previous quarter
JAZZ's ROIC is up by 10% QoQ

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 52% greater than the total liabilities
Jazz Pharmaceuticals's quick ratio has soared by 130% YoY and by 88% from the previous quarter
The company's current ratio has surged by 107% YoY and by 80% QoQ
The company's debt is 48% higher than its equity
Jazz Pharmaceuticals's equity has increased by 20% YoY and by 11% from the previous quarter
Jazz Pharmaceuticals's debt to equity has decreased by 11% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.